TNF and psoriasis: All of the non-TNF inhibitor monotherapy cohorts, except tofacitinib, were significantly associated with psoriasis when compared to methotrexate: tocilizumab ROR 5.31 and 95% CI [2.32–12.12], abatacept 4.63 [2.07–10.34], rituximab 3.83 [1.48–9.88], and tofacitinib 1.97 [0.85–4.58] (Table 4, Fig. 4).